Search | Clinical Trials Finder

Conditions: Crohns Disease
Interventions: TRX103, Cyclophosphamide; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: Indapta Therapeutics, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more

Conditions: Pemphigus
Interventions: cyclophosphamide, filgrastim; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions: Vatiquinone, Placebo; Drug · Other
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Up to 20 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: San Diego, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Stiff-Person Syndrome, SPS
Interventions: Standard lymphodepletion regimen; Biological
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Aurora, Colorado • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 22 more

Conditions: ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions: Registry, PK microsampling of blood; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Implant Procedure, Conventional Synthetic DMARD, Active stimulation, Non-active stimulation; Procedure · Drug · Device
Lead sponsor: SetPoint Medical Corporation; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 42
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions: Riliprubart, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 28
States / cities: Homewood, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Inherited Mitochondrial Disease
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: La Jolla, California • Stanford, California • New Haven, Connecticut + 10 more

Conditions: Refractory Autoimmune Diseases
Interventions: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab; Genetic · Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions: SC291; Biological
Lead sponsor: Sana Biotechnology; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Lupus Nephritis
Interventions: Obecabtagene autoleucel; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Syracuse, New York • San Antonio, Texas

Conditions: Autoimmune Thrombocytopenic Purpura
Interventions: Doxil; Drug
Lead sponsor: Hematology and Oncology Specialists; Other
Eligibility: 0 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Rheumatoid Arthritis
Interventions: GP2013, MabThera, Rituxan; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: Fostamatinib Disodium / R935788; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: H.P. Acthar gel; Drug
Lead sponsor: Iraj Sabahi Research Inc.; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Pleasanton, California • Turlock, California

Conditions: Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis
Interventions: IVIG; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse
Interventions: Alemtuzumab (Campath ), Cyclosporine; Biological · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 110 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Refractory Myasthenia Gravis
Interventions: Rituximab (Rituxan); Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Syracuse, New York • Burlington, Vermont

Conditions: Rheumatoid Arthritis (RA)
Interventions: Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Sham ultrasound stimulation (control), Conventional Synthetic DMARD; Device · Drug
Lead sponsor: SecondWave Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Glendale, Arizona • Covina, California • Temecula, California + 2 more

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: rapcabtagene autoleucel; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 17
States / cities: Birmingham, Alabama • San Bernardino, California • San Francisco, California + 10 more

Conditions: Systemic Lupus Erythematosus
Interventions: P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine, Rimiducid; Biological · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Birmingham, Alabama • Iowa City, Iowa

Search by objective public record fields.

Treatment of Moderate to Severe Refractory Crohn's Disease

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Alemtuzumab to Treat Severe Aplastic Anemia

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)